Table 1B.
Demographics by EGFR amplification status across all stage IV or recurrent esophagogastric cases in retrospective U of C cohort excluding those prospectively screened between 9/2014 and 12/2016.
| Characteristic | EGFR Amplified | EGFR Non-Amplified | P-Value |
|---|---|---|---|
| Number of patients (%) | 10 (7) | 134 (93) | P<2.2×10-16 |
| Median age yrs. (range) | 64.5 (37–77) | 62 (22–83) | 0.83 |
| Male Sex – no. (%) | 9 (90) | 93 (69) | 0.28 |
| Disease Site no. (%) | |||
| Esophagus/GEJ | 6 (60) | 63 (47) | 0.52 |
| Gastric | 4 (40) | 71 (53) | |
| Tumor Grade no. (%) | |||
| Well Differentiated | 0 (0) | 4 (3) | 0.76 |
| Moderately Differentiated | 1 (10) | 32 (24) | |
| Poorly Differentiated | 8 (80) | 97 (72) | |
| Unknown | 1 (10) | 1 (1) | |
| Stage at Diagnosis no. (%) | |||
| I | 0 (0) | 9 (7) | 0.94 |
| II | 0 (0) | 12 (9) | |
| III | 2 (20) | 30 (22) | |
| IV | 8 (80) | 83(62) | |
| Unknown | 0 (0) | 0 (0) | |
| HER2 – no. (%) | |||
| Positive | 3 (30) | 30 (22) | 0.74 |
| Negative | 6 (60) | 83 (62) | |
| Equivocal | 0 (0) | 11 (8) | |
| Unknown | 1 (10) | 10 (11) | |
| Race | |||
| Caucasian | 7 (70) | 104 (78) | 0.57 |
| African American | 2 (20) | 21 (16) | |
| Asian | 1 (10) | 9 (7) | |
| Hispanic | 0 (0) | 0 (0) |